董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Jeff Thramann | 男 | Director and Executive Chairman | 61 | 46.25万美元 | 0.0010 | 2026-03-18 |
| Brent Ness | 男 | Chief Executive Officer and Director and President | 59 | 46.25万美元 | 0.0011 | 2026-03-18 |
| David Neal | 男 | Director | 54 | 3.00万美元 | 0.0002 | 2026-03-18 |
| Steve Deitsch | 男 | Director | 54 | 5.25万美元 | 未持股 | 2026-03-18 |
| Scott Breidbart | 男 | Director | 70 | 4.50万美元 | 未持股 | 2026-03-18 |
| Amanda Williams | 女 | Director | 48 | 4.50万美元 | 未持股 | 2026-03-18 |
| William Wesemann | 男 | Director | 69 | 5.25万美元 | 0.0001 | 2026-03-18 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Jeff Thramann | 男 | Director and Executive Chairman | 61 | 46.25万美元 | 0.0010 | 2026-03-18 |
| Brent Ness | 男 | Chief Executive Officer and Director and President | 59 | 46.25万美元 | 0.0011 | 2026-03-18 |
| Ryan Bond | 男 | Chief Strategy Officer | 54 | 25.42万美元 | 0.0001 | 2026-03-18 |
| Gregory Gould | 男 | Chief Financial Officer | 59 | 12.66万美元 | 未持股 | 2026-03-18 |
董事简历
中英对照 | 中文 | 英文- Jeff Thramann
-
Jeff Thramann自2020年9月起担任董事。彼亦自2021年3月起担任本公司执行董事。自本招股说明书发布之日起，他将过渡为执行主席。他负责监督公司的战略举措、资本化和治理。这包括日常参与与高级管理层合作，以建立公司的战略愿景，协助KOL发展，与首席执行官和首席财务官就财务计划、临床报销和产品战略进行合作，协助首席执行官招聘和聘用高级管理人员以及开展业务发展活动。他的职责还包括领导投资者关系工作、建立董事会和领导董事会会议。Thramann博士目前是Auddia Inc.的创始人兼执行主席。纳斯达克：AUUD，一家技术公司，正在通过人工智能平台重塑消费者与音频的互动方式，该平台可实现跨广播和播客收听的独特消费者体验。Thramann博士于2012年1月创立了Auddia Inc.。自2021年2月以来，他在Auddia担任过与在Aclarion类似的职务。2002年，Thramann博士是LANX，LLC（& # 8220；LANX & # 8221；）的创始人（并成为董事长）。Lanx是一家专注于脊柱植入物市场的创新医疗器械公司，通过推出其专利Aspen产品创造了棘间过程融合空间。Lanx于2013年11月被出售给国际骨科集团Biomet，Inc.。与Lanx同时，Thramann博士于2006年7月成为Pronerve，LLC（& # 8220；Pronerve & # 8221；）的创始人兼董事长。Pronerve是一家医疗保健服务公司，在影响大脑和脊髓的高风险外科手术中提供神经功能监测。Pronerve于2012年被出售给私募股权公司Waud Capital Partners。在加入Pronerve之前并与Lanx同时任职，Thramann博士是美国放射外科的创始人兼主席。USR是一家医疗保健服务公司，为全身肿瘤提供先进的放射外科治疗。USR成为美国最大的机器人引导射波刀治疗此类肿瘤的供应商，并于2011年4月出售给Alliance Healthcare Services（纳斯达克股票代码：医疗保健 0）。从2001年7月到2008年4月，Thramann博士是Boulder Neurosurgical Associates的创始人和高级合伙人，这是一家为科罗拉多州博尔德县提供服务的神经外科诊所。Thramann博士是100多项美国和国际已发布和正在申请的专利的指定发明人。他于2001年6月在亚利桑那州凤凰城的巴罗神经学研究所完成了他的神经外科住院医师和复杂脊柱重建奖学金。他毕业于纽约市康奈尔大学医学院，并在纽约西点军校获得电气工程管理理学学士学位。
Jeff Thramann has been a director since September, 2020. He was also an executive Director since March of 2021, which is an executive officer of the Company. He transitioned to Executive Chairman at the time of April 2022 IPO. He oversees strategic initiatives, capitalization and governance at the company. This includes day to day involvement in working with senior management to establish the strategic vision of the Company, assist in KOL development, work with the Chief Executive Officer and Chief Financial Officer on financial plans, clinical reimbursement and product strategies, and assisting the Chief Executive Officer in recruitment and hiring of senior executives and the pursuit of biness development activities. His responsibilities also include leading investor relations efforts, building the board of directors and leading board meetings. Dr. Thramann is currently the founder and Executive Chairman of Auddia Inc. (NASDAQ: AUUD), a technology company that is reinventing how consumers interact with audio through an AI platform that enables unique consumer experiences across radio and podcast listening. Dr. Thramann founded Auddia Inc. in January 2012. In 2002, Dr. Thramann was the founder (and became the chairman) of Lanx, LLC ("Lanx"). Lanx was an innovative medical device company foced on the spinal implant market that created the interspino process fion space with the introduction of its patented Aspen product. Lanx was sold to Biomet, Inc., an international orthopedic conglomerate, in November, 2013. Concurrent with Lanx, in July, 2006 Dr. Thramann was the founder and chairman of ProNerve, LLC ("ProNerve"). ProNerve was a healthcare services company that provided monitoring of nerve function during high risk surgical procedures affecting the brain and spinal cord. ProNerve was sold to Waud Capital Partners, a private equity firm, in 2012. Prior to ProNerve and concurrent with Lanx, Dr. Thramann was the founder and chairman of U.S. Radiosurgery (R). R is a healthcare services company that provides advanced radiosurgical treatments for tumors throughout the body. R became the largest provider of robotic guided CyberKnife treatments of such tumors in the U.S. and was sold to Alliance Healthcare Services (NASDAQ: AIQ) in April, 2011. From July, 2001 through April, 2008, Dr. Thramann was the founder and senior partner of Boulder Neurosurgical Associates, a neurosurgical practice serving Boulder County, Colorado. Dr. Thramann is the named inventor on over 100 U.S. and international issued and pending patents. He completed his neurosurgical residency and complex spinal reconstruction fellowship at the Barrow Neurological Institute in Phoenix, AZ, in June, 2001. He is a graduate of Cornell University Medical College in New York City and earned his Bachelor of Science degree in electrical engineering management at the U. S. Military Academy in st Point, NY. - Jeff Thramann自2020年9月起担任董事。彼亦自2021年3月起担任本公司执行董事。自本招股说明书发布之日起，他将过渡为执行主席。他负责监督公司的战略举措、资本化和治理。这包括日常参与与高级管理层合作，以建立公司的战略愿景，协助KOL发展，与首席执行官和首席财务官就财务计划、临床报销和产品战略进行合作，协助首席执行官招聘和聘用高级管理人员以及开展业务发展活动。他的职责还包括领导投资者关系工作、建立董事会和领导董事会会议。Thramann博士目前是Auddia Inc.的创始人兼执行主席。纳斯达克：AUUD，一家技术公司，正在通过人工智能平台重塑消费者与音频的互动方式，该平台可实现跨广播和播客收听的独特消费者体验。Thramann博士于2012年1月创立了Auddia Inc.。自2021年2月以来，他在Auddia担任过与在Aclarion类似的职务。2002年，Thramann博士是LANX，LLC（& # 8220；LANX & # 8221；）的创始人（并成为董事长）。Lanx是一家专注于脊柱植入物市场的创新医疗器械公司，通过推出其专利Aspen产品创造了棘间过程融合空间。Lanx于2013年11月被出售给国际骨科集团Biomet，Inc.。与Lanx同时，Thramann博士于2006年7月成为Pronerve，LLC（& # 8220；Pronerve & # 8221；）的创始人兼董事长。Pronerve是一家医疗保健服务公司，在影响大脑和脊髓的高风险外科手术中提供神经功能监测。Pronerve于2012年被出售给私募股权公司Waud Capital Partners。在加入Pronerve之前并与Lanx同时任职，Thramann博士是美国放射外科的创始人兼主席。USR是一家医疗保健服务公司，为全身肿瘤提供先进的放射外科治疗。USR成为美国最大的机器人引导射波刀治疗此类肿瘤的供应商，并于2011年4月出售给Alliance Healthcare Services（纳斯达克股票代码：医疗保健 0）。从2001年7月到2008年4月，Thramann博士是Boulder Neurosurgical Associates的创始人和高级合伙人，这是一家为科罗拉多州博尔德县提供服务的神经外科诊所。Thramann博士是100多项美国和国际已发布和正在申请的专利的指定发明人。他于2001年6月在亚利桑那州凤凰城的巴罗神经学研究所完成了他的神经外科住院医师和复杂脊柱重建奖学金。他毕业于纽约市康奈尔大学医学院，并在纽约西点军校获得电气工程管理理学学士学位。
- Jeff Thramann has been a director since September, 2020. He was also an executive Director since March of 2021, which is an executive officer of the Company. He transitioned to Executive Chairman at the time of April 2022 IPO. He oversees strategic initiatives, capitalization and governance at the company. This includes day to day involvement in working with senior management to establish the strategic vision of the Company, assist in KOL development, work with the Chief Executive Officer and Chief Financial Officer on financial plans, clinical reimbursement and product strategies, and assisting the Chief Executive Officer in recruitment and hiring of senior executives and the pursuit of biness development activities. His responsibilities also include leading investor relations efforts, building the board of directors and leading board meetings. Dr. Thramann is currently the founder and Executive Chairman of Auddia Inc. (NASDAQ: AUUD), a technology company that is reinventing how consumers interact with audio through an AI platform that enables unique consumer experiences across radio and podcast listening. Dr. Thramann founded Auddia Inc. in January 2012. In 2002, Dr. Thramann was the founder (and became the chairman) of Lanx, LLC ("Lanx"). Lanx was an innovative medical device company foced on the spinal implant market that created the interspino process fion space with the introduction of its patented Aspen product. Lanx was sold to Biomet, Inc., an international orthopedic conglomerate, in November, 2013. Concurrent with Lanx, in July, 2006 Dr. Thramann was the founder and chairman of ProNerve, LLC ("ProNerve"). ProNerve was a healthcare services company that provided monitoring of nerve function during high risk surgical procedures affecting the brain and spinal cord. ProNerve was sold to Waud Capital Partners, a private equity firm, in 2012. Prior to ProNerve and concurrent with Lanx, Dr. Thramann was the founder and chairman of U.S. Radiosurgery (R). R is a healthcare services company that provides advanced radiosurgical treatments for tumors throughout the body. R became the largest provider of robotic guided CyberKnife treatments of such tumors in the U.S. and was sold to Alliance Healthcare Services (NASDAQ: AIQ) in April, 2011. From July, 2001 through April, 2008, Dr. Thramann was the founder and senior partner of Boulder Neurosurgical Associates, a neurosurgical practice serving Boulder County, Colorado. Dr. Thramann is the named inventor on over 100 U.S. and international issued and pending patents. He completed his neurosurgical residency and complex spinal reconstruction fellowship at the Barrow Neurological Institute in Phoenix, AZ, in June, 2001. He is a graduate of Cornell University Medical College in New York City and earned his Bachelor of Science degree in electrical engineering management at the U. S. Military Academy in st Point, NY.
- Brent Ness
-
Brent Ness于2021年9月15日成为我们的首席执行官。从2019年12月到2021年4月，他担任顾问，然后成为Cleerly，Inc.的总裁兼首席商务官。Cleerly是支持AI的非侵入性数字护理途径的开发商，旨在提高临床医生对患者冠状动脉猝死风险的理解。在Cleerly，Ness先生共同领导与佳能公司建立合作伙伴关系，佳能公司共同营销Cleerly解决方案作为其产品的一部分。从2016年3月到2019年12月，Ness先生担任Mighty Oak Medical（& # 8220；Mighty Oak & # 8221；）的首席运营官，该公司的主要产品从FDA批准前发展到其名为Firefly的平台的国际全面市场推出。Firefly是一种3D打印的患者专用解决方案，旨在为脊柱外科医生提供一种高精度的替代方案，以替代脊柱导航空间中的导航和机器人应用。Firefly涉及使用CT扫描作为核心数据，根据这些数据创建复杂的术前计划以及指南和骨骼模型。从2014年到2016年，Ness先生担任Heartflow，Inc.（& # 8220；Heartflow & # 8221；）的首席商务官。HeartFlow是一家医疗技术公司，创建并开发了一种无创心脏测试，使医生能够为疑似冠心病患者做出更明智的决定。Ness先生领导的业务从FDA批准前到早期采用者网站的全球扩张。他与HeartFlow的高级领导团队一起，在SaaS平台的早期推出中部署了强大的临床循证方法，以吸引关键意见领袖医生和第三方付款人社区。这导致发布了III类CPT代码和多个私人付款人承保决定。从从2008年到2013年，他担任Pronerve，LLC（& # 8220；Pronerve”）的总裁。Pronerve是术中神经监测服务的提供商，涉及在脊柱和脑部手术期间使用各种电生理监测程序，以实现预警并避免对神经系统结构的损伤。作为Pronerve的总裁，Ness先生主持了高度分散的术中神经监测行业的总结。从2004年到2008年，Ness先生担任Medtronic Navigation（美敦力公司的一个部门）的全球销售与市场营销副总裁。在他职业生涯的早期，他曾受雇于通用电气医疗保健公司担任公司客户总监，并在飞利浦北美公司担任销售运营副总裁，这些公司是诊断成像设备的供应商。Ness目前担任Mighty Oak Medical、K2 Capital和Cleerly的顾问。Ness先生拥有北达科他大学市场营销学士学位和科罗拉多大学工商管理硕士学位。
Brent Ness became Chief Executive Officer on September 15, 2021. From December 2019 through April 2021, he was a consultant and then became President and Chief Commercial Officer of Cleerly, Inc., ("Cleerly"). Cleerly is a developer of an AI enabled non invasive digital care pathway aimed at improving clinicians understanding of their patients' risk of sudden coronary death. At Cleerly, Mr. Ness co led efforts to create a partnership with Canon, Inc. who co markets Cleerly solutions as part of their offerings. From March 2016 to December 2019, Mr. Ness was the Chief Operating Officer of Mighty Oak Medical ("Mighty Oak") whose principal products progressed from pre FDA clearance through an international full market launch of their platform called FIREFLY. FIREFLY is a 3D Printed patient specific solution that is intended to provide spine surgeons with a highly accurate alternative to navigation and robotic applications in the spinal navigation space. FIREFLY involves the e of CT scans as the core data upon which sophisticated pre surgical plans are created along with guides and bone models. From 2014 through 2016, Mr. Ness was the Chief Commercial Officer of HeartFlow, Inc., ("Heartflow"). HeartFlow is a medical technology company that created and developed a non invasive cardiac test enabling physicians to make more informed decisions for their patients with spected coronary heart disease. Mr. Ness led the biness from pre FDA clearance through a global expansion of early adopter sites. Along with the senior leadership team at HeartFlow, he deployed a strong clinical evidence based approach in the early launch of the SaaS platform to engage Key Opinion Leader Physicians and the third party payer community. This resulted in the issuance of Category III CPT Codes and multiple private payer coverage decisions. From 2008 through 2013, he was President of ProNerve, LLC, ("ProNerve"). ProNerve is a provider of intraoperative neuromonitoring services which involves the e of a variety of electro physiological monitoring procedures during spine and brain surgery, to allow early warning and avoidance of injury to nervo system structures. As President of ProNerve, Mr. Ness presided over a roll up of the highly fragmented Interoperative Nerve Monitoring Indtry. From 2004 to 2008, Mr. Ness served as Vice President Global Sales and Marketing for Medtronic Navigation, a division of Medtronic, Inc. Earlier in his career he was employed by GE Healthcare as Director of Corporate Accounts and for Philips North America as Vice President of Sales Operations, which companies are suppliers of diagnostic imaging equipment. - Brent Ness于2021年9月15日成为我们的首席执行官。从2019年12月到2021年4月，他担任顾问，然后成为Cleerly，Inc.的总裁兼首席商务官。Cleerly是支持AI的非侵入性数字护理途径的开发商，旨在提高临床医生对患者冠状动脉猝死风险的理解。在Cleerly，Ness先生共同领导与佳能公司建立合作伙伴关系，佳能公司共同营销Cleerly解决方案作为其产品的一部分。从2016年3月到2019年12月，Ness先生担任Mighty Oak Medical（& # 8220；Mighty Oak & # 8221；）的首席运营官，该公司的主要产品从FDA批准前发展到其名为Firefly的平台的国际全面市场推出。Firefly是一种3D打印的患者专用解决方案，旨在为脊柱外科医生提供一种高精度的替代方案，以替代脊柱导航空间中的导航和机器人应用。Firefly涉及使用CT扫描作为核心数据，根据这些数据创建复杂的术前计划以及指南和骨骼模型。从2014年到2016年，Ness先生担任Heartflow，Inc.（& # 8220；Heartflow & # 8221；）的首席商务官。HeartFlow是一家医疗技术公司，创建并开发了一种无创心脏测试，使医生能够为疑似冠心病患者做出更明智的决定。Ness先生领导的业务从FDA批准前到早期采用者网站的全球扩张。他与HeartFlow的高级领导团队一起，在SaaS平台的早期推出中部署了强大的临床循证方法，以吸引关键意见领袖医生和第三方付款人社区。这导致发布了III类CPT代码和多个私人付款人承保决定。从从2008年到2013年，他担任Pronerve，LLC（& # 8220；Pronerve”）的总裁。Pronerve是术中神经监测服务的提供商，涉及在脊柱和脑部手术期间使用各种电生理监测程序，以实现预警并避免对神经系统结构的损伤。作为Pronerve的总裁，Ness先生主持了高度分散的术中神经监测行业的总结。从2004年到2008年，Ness先生担任Medtronic Navigation（美敦力公司的一个部门）的全球销售与市场营销副总裁。在他职业生涯的早期，他曾受雇于通用电气医疗保健公司担任公司客户总监，并在飞利浦北美公司担任销售运营副总裁，这些公司是诊断成像设备的供应商。Ness目前担任Mighty Oak Medical、K2 Capital和Cleerly的顾问。Ness先生拥有北达科他大学市场营销学士学位和科罗拉多大学工商管理硕士学位。
- Brent Ness became Chief Executive Officer on September 15, 2021. From December 2019 through April 2021, he was a consultant and then became President and Chief Commercial Officer of Cleerly, Inc., ("Cleerly"). Cleerly is a developer of an AI enabled non invasive digital care pathway aimed at improving clinicians understanding of their patients' risk of sudden coronary death. At Cleerly, Mr. Ness co led efforts to create a partnership with Canon, Inc. who co markets Cleerly solutions as part of their offerings. From March 2016 to December 2019, Mr. Ness was the Chief Operating Officer of Mighty Oak Medical ("Mighty Oak") whose principal products progressed from pre FDA clearance through an international full market launch of their platform called FIREFLY. FIREFLY is a 3D Printed patient specific solution that is intended to provide spine surgeons with a highly accurate alternative to navigation and robotic applications in the spinal navigation space. FIREFLY involves the e of CT scans as the core data upon which sophisticated pre surgical plans are created along with guides and bone models. From 2014 through 2016, Mr. Ness was the Chief Commercial Officer of HeartFlow, Inc., ("Heartflow"). HeartFlow is a medical technology company that created and developed a non invasive cardiac test enabling physicians to make more informed decisions for their patients with spected coronary heart disease. Mr. Ness led the biness from pre FDA clearance through a global expansion of early adopter sites. Along with the senior leadership team at HeartFlow, he deployed a strong clinical evidence based approach in the early launch of the SaaS platform to engage Key Opinion Leader Physicians and the third party payer community. This resulted in the issuance of Category III CPT Codes and multiple private payer coverage decisions. From 2008 through 2013, he was President of ProNerve, LLC, ("ProNerve"). ProNerve is a provider of intraoperative neuromonitoring services which involves the e of a variety of electro physiological monitoring procedures during spine and brain surgery, to allow early warning and avoidance of injury to nervo system structures. As President of ProNerve, Mr. Ness presided over a roll up of the highly fragmented Interoperative Nerve Monitoring Indtry. From 2004 to 2008, Mr. Ness served as Vice President Global Sales and Marketing for Medtronic Navigation, a division of Medtronic, Inc. Earlier in his career he was employed by GE Healthcare as Director of Corporate Accounts and for Philips North America as Vice President of Sales Operations, which companies are suppliers of diagnostic imaging equipment.
- David Neal
-
David Neal自2016年9月起担任董事。他是2016年成立的SC Capital 1 LLC的创始人和现任成员。SC Capital 1 LLC是一家证券化有限责任公司，旨在投资突破性医疗技术和疗法。此外，从2015年4月至今，他一直是Frontier Wealth Enterprises，LLC的合伙人，这是一家为高净值家庭提供基于建议的金融服务的金融服务公司。从2000年到2015年，他在瑞银担任过多个职位，包括投资组合经理和堪萨斯州威奇托地区办事处经理。他在哈钦森地区医疗中心董事会任职9年，目前是哈钦森社区基金会的董事会成员。他拥有堪萨斯大学运动科学学士学位和圣路易斯大学约翰库克商学院管理科学硕士学位。
David Neal has been on the Aclarion Board of Directors since September 2016. He is the founder of SC Capital 1 LLC, a securitized LLC formed to invest in breakthrough medical technologies and therapies. He is a senior vice president at CAPTRT, one of the nation's largest financial advisory firms. Prior to merging with CAPTRT, David was a partner at Frontier alth Management from April 2015 until July 2022. From 2000 to 2015, he held vario positions at UBS, including Portfolio Manager and regional manager in Wichita, Kansas. He currently serves as Chairman of the Board for the foundation of Cosmosphere, a Smithsonian affiliated world class Space meum. He is a past president of the board of the Kansas Chapter of the Leukemia & Lymphoma Society, and served 9 years on the Hutchinson Regional Medical Center board of directors. In 2006, David and his wife, Karin, founded the John & Michael Neal Foundation for Cancer Research, where they continue to raise money for vario cancer research projects and fund vario research medical projects. David holds a Bachelor of Sport Science degree from the University of Kansas and a Master of Management Science degree from the John Cook School of Biness at Saint Louis University. - David Neal自2016年9月起担任董事。他是2016年成立的SC Capital 1 LLC的创始人和现任成员。SC Capital 1 LLC是一家证券化有限责任公司，旨在投资突破性医疗技术和疗法。此外，从2015年4月至今，他一直是Frontier Wealth Enterprises，LLC的合伙人，这是一家为高净值家庭提供基于建议的金融服务的金融服务公司。从2000年到2015年，他在瑞银担任过多个职位，包括投资组合经理和堪萨斯州威奇托地区办事处经理。他在哈钦森地区医疗中心董事会任职9年，目前是哈钦森社区基金会的董事会成员。他拥有堪萨斯大学运动科学学士学位和圣路易斯大学约翰库克商学院管理科学硕士学位。
- David Neal has been on the Aclarion Board of Directors since September 2016. He is the founder of SC Capital 1 LLC, a securitized LLC formed to invest in breakthrough medical technologies and therapies. He is a senior vice president at CAPTRT, one of the nation's largest financial advisory firms. Prior to merging with CAPTRT, David was a partner at Frontier alth Management from April 2015 until July 2022. From 2000 to 2015, he held vario positions at UBS, including Portfolio Manager and regional manager in Wichita, Kansas. He currently serves as Chairman of the Board for the foundation of Cosmosphere, a Smithsonian affiliated world class Space meum. He is a past president of the board of the Kansas Chapter of the Leukemia & Lymphoma Society, and served 9 years on the Hutchinson Regional Medical Center board of directors. In 2006, David and his wife, Karin, founded the John & Michael Neal Foundation for Cancer Research, where they continue to raise money for vario cancer research projects and fund vario research medical projects. David holds a Bachelor of Sport Science degree from the University of Kansas and a Master of Management Science degree from the John Cook School of Biness at Saint Louis University.
- Steve Deitsch
-
Steve Deitsch目前是Paradigm 28的首席财务官，这是一家专注于足踝手术植入物的医疗器械公司。史蒂夫在上市公司和私营公司拥有丰富的战略、运营和财务领导经验。2017年4月至2019年8月，Deitsch先生担任高级副总裁和首席财务官（现为Option Care Health，Inc.的一部分）。纳斯达克：BIOS。2015年8月至2017年4月，Deitsch先生担任凯雷集团旗下领先的网络安全公司Coalfire，Inc.的执行副总裁、0和公司秘书。Steve于2014年7月至2015年7月担任Zimmer Biomet脊柱、骨愈合和微固定业务的副总裁，并于2014年2月至2014年7月担任Biomet公司财务总监。Deitsch先生自2009年9月起担任Lanx的首席财务官，直至2013年10月被Biomet收购。从2002年到2009年，Deitsch先生还在Zimmer Holdings，Inc.（现为Zimmer Biomet，Inc.的一部分）担任过各种高级财务领导职务，包括财务、重建和运营副总裁以及欧洲财务副总裁。史蒂夫是私人控股医疗器械公司Green Sun Medical的董事，自2017年10月起担任该职位，并自2021年2月起担任Auddia Inc.（纳斯达克股票代码：AUUD）的董事和审计委员会主席。
Steve Deitsch is the Chief Financial Officer of OrganOx Ltd., a University of Oxford spinout and global leader in normothermic machine perfion organ transplant technology, which was sold to Terumo Corporation in late 2025 for $1.5 billion. From September 2020 to April 2024, Mr. Deitsch served as Chief Financial Officer of Paragon 28 (formerly NYSE: FNA), a leading medical device company foced on foot and ankle surgical implants. From April 2017 to Augt 2019, he served as Chief Financial Officer of home healthcare leader BioScrip, Inc. (formerly NASDAQ: BIOS), which merged with Option Care Health, Inc. in 2019. Previoly, Mr. Deitsch served as Chief Financial Officer of cybersecurity firm Coalfire, Inc. from 2015 to 2017 and Lanx, Inc., a spinal medical device company that was acquired by Biomet in 2013. Earlier in his career, he spent seven years in vario senior financial leadership roles at Zimmer Holdings, Inc. (now part of Zimmer Biomet, Inc.) pl over seven years with Deloitte and Ernst & Young. Mr. Deitsch currently also serves as a director of Caristo Diagnostics Ltd., a privately held University of Oxford spinout and global leader in AI pored cardiovascular disease detection. He holds a B.S. in Accounting from Ball State University and is a licensed CPA (inactive). - Steve Deitsch目前是Paradigm 28的首席财务官，这是一家专注于足踝手术植入物的医疗器械公司。史蒂夫在上市公司和私营公司拥有丰富的战略、运营和财务领导经验。2017年4月至2019年8月，Deitsch先生担任高级副总裁和首席财务官（现为Option Care Health，Inc.的一部分）。纳斯达克：BIOS。2015年8月至2017年4月，Deitsch先生担任凯雷集团旗下领先的网络安全公司Coalfire，Inc.的执行副总裁、0和公司秘书。Steve于2014年7月至2015年7月担任Zimmer Biomet脊柱、骨愈合和微固定业务的副总裁，并于2014年2月至2014年7月担任Biomet公司财务总监。Deitsch先生自2009年9月起担任Lanx的首席财务官，直至2013年10月被Biomet收购。从2002年到2009年，Deitsch先生还在Zimmer Holdings，Inc.（现为Zimmer Biomet，Inc.的一部分）担任过各种高级财务领导职务，包括财务、重建和运营副总裁以及欧洲财务副总裁。史蒂夫是私人控股医疗器械公司Green Sun Medical的董事，自2017年10月起担任该职位，并自2021年2月起担任Auddia Inc.（纳斯达克股票代码：AUUD）的董事和审计委员会主席。
- Steve Deitsch is the Chief Financial Officer of OrganOx Ltd., a University of Oxford spinout and global leader in normothermic machine perfion organ transplant technology, which was sold to Terumo Corporation in late 2025 for $1.5 billion. From September 2020 to April 2024, Mr. Deitsch served as Chief Financial Officer of Paragon 28 (formerly NYSE: FNA), a leading medical device company foced on foot and ankle surgical implants. From April 2017 to Augt 2019, he served as Chief Financial Officer of home healthcare leader BioScrip, Inc. (formerly NASDAQ: BIOS), which merged with Option Care Health, Inc. in 2019. Previoly, Mr. Deitsch served as Chief Financial Officer of cybersecurity firm Coalfire, Inc. from 2015 to 2017 and Lanx, Inc., a spinal medical device company that was acquired by Biomet in 2013. Earlier in his career, he spent seven years in vario senior financial leadership roles at Zimmer Holdings, Inc. (now part of Zimmer Biomet, Inc.) pl over seven years with Deloitte and Ernst & Young. Mr. Deitsch currently also serves as a director of Caristo Diagnostics Ltd., a privately held University of Oxford spinout and global leader in AI pored cardiovascular disease detection. He holds a B.S. in Accounting from Ball State University and is a licensed CPA (inactive).
- Scott Breidbart
-
Scott Breidbart自2018年1月起担任Affinity Health Plans的首席医疗官。Affinity Health Plan是一个独立的非营利组织，成立于1986年，旨在为服务不足的纽约人提供负担得起的高质量医疗保险。2016年10月至2018年1月，他担任Solera Health的首席医疗官，2015年10月至2016年9月，他担任Emblem Health的首席临床官。2008年11月至2015年10月，Breidbart先生担任Empire BlueCross BlueShield的首席医疗官，1998年5月至2008年8月，他在HealthNet的医疗管理方面担任过各种职务。Breidbart博士在纽约医学院任教十年，从事儿科内分泌学工作。他获得了儿科和儿科内分泌学的委员会认证，并获得了在纽约行医的许可。他拥有耶鲁大学数学学士学位、哥伦比亚大学医学博士学位和佩斯大学工商管理硕士学位。
Scott Breidbart has been consulting in the healthcare indtry since November 2021. Before that, he was the Chief Medical Officer of Affinity Health Plans from January 2018 until its purchase in November 2021. From October 2016 to January 2018, he was Chief Medical Officer of Solera Health and from October 2015 to September 2016, he was the Chief Clinical Officer of Emblem Health. From November 2008 to October 2015, Mr. Breidbart served as the Chief Medical Officer of Empire BlueCross BlueShield, and from May 1998 to Augt 2008 he had vario roles in medical management for HealthNet. Dr. Breidbart practiced pediatric endocrinology for ten years on the faculty of New York Medical College. He is Board Certified in Pediatrics and Pediatric Endocrinology and is licensed to practice medicine in NY. He holds a BA in Mathematics from Yale, an MD from Columbia, and an MBA from Pace University. - Scott Breidbart自2018年1月起担任Affinity Health Plans的首席医疗官。Affinity Health Plan是一个独立的非营利组织，成立于1986年，旨在为服务不足的纽约人提供负担得起的高质量医疗保险。2016年10月至2018年1月，他担任Solera Health的首席医疗官，2015年10月至2016年9月，他担任Emblem Health的首席临床官。2008年11月至2015年10月，Breidbart先生担任Empire BlueCross BlueShield的首席医疗官，1998年5月至2008年8月，他在HealthNet的医疗管理方面担任过各种职务。Breidbart博士在纽约医学院任教十年，从事儿科内分泌学工作。他获得了儿科和儿科内分泌学的委员会认证，并获得了在纽约行医的许可。他拥有耶鲁大学数学学士学位、哥伦比亚大学医学博士学位和佩斯大学工商管理硕士学位。
- Scott Breidbart has been consulting in the healthcare indtry since November 2021. Before that, he was the Chief Medical Officer of Affinity Health Plans from January 2018 until its purchase in November 2021. From October 2016 to January 2018, he was Chief Medical Officer of Solera Health and from October 2015 to September 2016, he was the Chief Clinical Officer of Emblem Health. From November 2008 to October 2015, Mr. Breidbart served as the Chief Medical Officer of Empire BlueCross BlueShield, and from May 1998 to Augt 2008 he had vario roles in medical management for HealthNet. Dr. Breidbart practiced pediatric endocrinology for ten years on the faculty of New York Medical College. He is Board Certified in Pediatrics and Pediatric Endocrinology and is licensed to practice medicine in NY. He holds a BA in Mathematics from Yale, an MD from Columbia, and an MBA from Pace University.
- Amanda Williams
-
阿曼达威廉姆斯，最近在ViewRay公司（纳斯达克：VRAY）担任临床、质量和监管高级副总裁，该公司是一家医疗保健公司，将肿瘤的实时核磁共振成像与高剂量辐射相结合，以提高治疗的准确性。2017年12月至2018年9月，她担任飞利浦图像引导治疗设备和系统部门的监管主管。2010年7月至2017年12月，Sequira女士担任The Spectranetics公司（现为飞利浦的一部分）临床和监管高级总监（2010-2013年）和副总裁（2013-2017年），2003年至2010年，她担任AGA医疗公司（现为雅培的一部分）的经理和监管总监。在担任这些职务之前，她曾在微管医疗仪器担任监管专家，在GE – Osmonics担任化学家。在这些职位上，她开发了多种产品，包括心血管治疗、植入式心脏缺陷设备、组合药物/设备和大型资本设备（包括成像和治疗）设备。在Spectranetics，她领导的团队完成了多项全球随机临床研究。她拥有美国东北大学法规学硕士学位和明尼苏达大学化学学学士学位。
Amanda Williams has been Senior Vice President for Clinical and Regulatory at MedAlliance, a Cordis company, which is a healthcare company foced on treating peripheral and coronary artery disease with the Selution drug coated balloon, since August 2023. From September 2018 to May 2023, she was the Senior Vice President of Clinical, Quality and Regulatory at ViewRay, Inc. (Nasdaq: VRAY), a healthcare company that integrates real time MRI imaging of tumors with the delivery of high dose radiation for improved treatment accuracy. From December, 2017, to September, 2018, she was the Head of Regulatory with the Image Guided Therapy Devices and Systems divisions of Philips. From July, 2010 to December, 2017 Ms. Sequira was the Senior Director (2010 2013) and Vice President (2013 2017) of Clinical and Regulatory with The Spectranetics Corp., (now part of Philips), and from 2003 to 2010 she was Manager, and then Director of Regulatory of AGA Medical Corp (now part of Abbott). Prior to these roles, she worked as a Regulatory Specialist with Vascular Solutions and as a Chemist with GE – Osmonics. In these positions, she worked on a diverse range of products, including cardiovascular treatment, implantable heart defect device, combination drug/device and large capital equipment (both imaging and treatment) devices. At Spectranetics, she led teams that completed multiple global randomized clinical studies. She holds a Master of Science in Regulatory from Northeastern University and a Bachelor of Science in Chemistry from the University of Minnesota. - 阿曼达威廉姆斯，最近在ViewRay公司（纳斯达克：VRAY）担任临床、质量和监管高级副总裁，该公司是一家医疗保健公司，将肿瘤的实时核磁共振成像与高剂量辐射相结合，以提高治疗的准确性。2017年12月至2018年9月，她担任飞利浦图像引导治疗设备和系统部门的监管主管。2010年7月至2017年12月，Sequira女士担任The Spectranetics公司（现为飞利浦的一部分）临床和监管高级总监（2010-2013年）和副总裁（2013-2017年），2003年至2010年，她担任AGA医疗公司（现为雅培的一部分）的经理和监管总监。在担任这些职务之前，她曾在微管医疗仪器担任监管专家，在GE – Osmonics担任化学家。在这些职位上，她开发了多种产品，包括心血管治疗、植入式心脏缺陷设备、组合药物/设备和大型资本设备（包括成像和治疗）设备。在Spectranetics，她领导的团队完成了多项全球随机临床研究。她拥有美国东北大学法规学硕士学位和明尼苏达大学化学学学士学位。
- Amanda Williams has been Senior Vice President for Clinical and Regulatory at MedAlliance, a Cordis company, which is a healthcare company foced on treating peripheral and coronary artery disease with the Selution drug coated balloon, since August 2023. From September 2018 to May 2023, she was the Senior Vice President of Clinical, Quality and Regulatory at ViewRay, Inc. (Nasdaq: VRAY), a healthcare company that integrates real time MRI imaging of tumors with the delivery of high dose radiation for improved treatment accuracy. From December, 2017, to September, 2018, she was the Head of Regulatory with the Image Guided Therapy Devices and Systems divisions of Philips. From July, 2010 to December, 2017 Ms. Sequira was the Senior Director (2010 2013) and Vice President (2013 2017) of Clinical and Regulatory with The Spectranetics Corp., (now part of Philips), and from 2003 to 2010 she was Manager, and then Director of Regulatory of AGA Medical Corp (now part of Abbott). Prior to these roles, she worked as a Regulatory Specialist with Vascular Solutions and as a Chemist with GE – Osmonics. In these positions, she worked on a diverse range of products, including cardiovascular treatment, implantable heart defect device, combination drug/device and large capital equipment (both imaging and treatment) devices. At Spectranetics, she led teams that completed multiple global randomized clinical studies. She holds a Master of Science in Regulatory from Northeastern University and a Bachelor of Science in Chemistry from the University of Minnesota.
- William Wesemann
-
William Wesemann，自2016年起担任董事。Wesemann先生自2002年6月以来一直是一名独立的商人和投资者。在2002年之前，他的经历包括在科技公司担任首席执行官、销售领导和顾问职务。自2004年起，他一直担任LivePerson（纳斯达克：LPSN）的董事，该公司是一家开发会话式商务和AI软件的全球技术公司。他还是消费者社交音频平台Stationhead，Inc.（2019年开始）的董事；以及照片管理公司Mylio，Inc（2013年开始）的董事。Wesemann先生获得了Glassboro State College （Rowan University）的学士学位。
William Wesemann has been a director since 2016. Mr. semann has been an independent binessman and investor since June 2002. Prior to 2002 his experience included serving in chief executive, sales leadership, and advisory roles at technology companies. Since 2004, he has been a director of LivePerson (Nasdaq: LPSN), a global technology company that develops conversational commerce and AI software. He is also a director of Stationhead, Inc. (commencing in 2019), a consumer social audio platform; and a director of Mylio, Inc (commencing in 2013) a photo management company. Mr. semann received a B.A. from Glassboro State College (Rowan University). - William Wesemann，自2016年起担任董事。Wesemann先生自2002年6月以来一直是一名独立的商人和投资者。在2002年之前，他的经历包括在科技公司担任首席执行官、销售领导和顾问职务。自2004年起，他一直担任LivePerson（纳斯达克：LPSN）的董事，该公司是一家开发会话式商务和AI软件的全球技术公司。他还是消费者社交音频平台Stationhead，Inc.（2019年开始）的董事；以及照片管理公司Mylio，Inc（2013年开始）的董事。Wesemann先生获得了Glassboro State College （Rowan University）的学士学位。
- William Wesemann has been a director since 2016. Mr. semann has been an independent binessman and investor since June 2002. Prior to 2002 his experience included serving in chief executive, sales leadership, and advisory roles at technology companies. Since 2004, he has been a director of LivePerson (Nasdaq: LPSN), a global technology company that develops conversational commerce and AI software. He is also a director of Stationhead, Inc. (commencing in 2019), a consumer social audio platform; and a director of Mylio, Inc (commencing in 2013) a photo management company. Mr. semann received a B.A. from Glassboro State College (Rowan University).
高管简历
中英对照 | 中文 | 英文- Jeff Thramann
Jeff Thramann自2020年9月起担任董事。彼亦自2021年3月起担任本公司执行董事。自本招股说明书发布之日起，他将过渡为执行主席。他负责监督公司的战略举措、资本化和治理。这包括日常参与与高级管理层合作，以建立公司的战略愿景，协助KOL发展，与首席执行官和首席财务官就财务计划、临床报销和产品战略进行合作，协助首席执行官招聘和聘用高级管理人员以及开展业务发展活动。他的职责还包括领导投资者关系工作、建立董事会和领导董事会会议。Thramann博士目前是Auddia Inc.的创始人兼执行主席。纳斯达克：AUUD，一家技术公司，正在通过人工智能平台重塑消费者与音频的互动方式，该平台可实现跨广播和播客收听的独特消费者体验。Thramann博士于2012年1月创立了Auddia Inc.。自2021年2月以来，他在Auddia担任过与在Aclarion类似的职务。2002年，Thramann博士是LANX，LLC（& # 8220；LANX & # 8221；）的创始人（并成为董事长）。Lanx是一家专注于脊柱植入物市场的创新医疗器械公司，通过推出其专利Aspen产品创造了棘间过程融合空间。Lanx于2013年11月被出售给国际骨科集团Biomet，Inc.。与Lanx同时，Thramann博士于2006年7月成为Pronerve，LLC（& # 8220；Pronerve & # 8221；）的创始人兼董事长。Pronerve是一家医疗保健服务公司，在影响大脑和脊髓的高风险外科手术中提供神经功能监测。Pronerve于2012年被出售给私募股权公司Waud Capital Partners。在加入Pronerve之前并与Lanx同时任职，Thramann博士是美国放射外科的创始人兼主席。USR是一家医疗保健服务公司，为全身肿瘤提供先进的放射外科治疗。USR成为美国最大的机器人引导射波刀治疗此类肿瘤的供应商，并于2011年4月出售给Alliance Healthcare Services（纳斯达克股票代码：医疗保健 0）。从2001年7月到2008年4月，Thramann博士是Boulder Neurosurgical Associates的创始人和高级合伙人，这是一家为科罗拉多州博尔德县提供服务的神经外科诊所。Thramann博士是100多项美国和国际已发布和正在申请的专利的指定发明人。他于2001年6月在亚利桑那州凤凰城的巴罗神经学研究所完成了他的神经外科住院医师和复杂脊柱重建奖学金。他毕业于纽约市康奈尔大学医学院，并在纽约西点军校获得电气工程管理理学学士学位。
Jeff Thramann has been a director since September, 2020. He was also an executive Director since March of 2021, which is an executive officer of the Company. He transitioned to Executive Chairman at the time of April 2022 IPO. He oversees strategic initiatives, capitalization and governance at the company. This includes day to day involvement in working with senior management to establish the strategic vision of the Company, assist in KOL development, work with the Chief Executive Officer and Chief Financial Officer on financial plans, clinical reimbursement and product strategies, and assisting the Chief Executive Officer in recruitment and hiring of senior executives and the pursuit of biness development activities. His responsibilities also include leading investor relations efforts, building the board of directors and leading board meetings. Dr. Thramann is currently the founder and Executive Chairman of Auddia Inc. (NASDAQ: AUUD), a technology company that is reinventing how consumers interact with audio through an AI platform that enables unique consumer experiences across radio and podcast listening. Dr. Thramann founded Auddia Inc. in January 2012. In 2002, Dr. Thramann was the founder (and became the chairman) of Lanx, LLC ("Lanx"). Lanx was an innovative medical device company foced on the spinal implant market that created the interspino process fion space with the introduction of its patented Aspen product. Lanx was sold to Biomet, Inc., an international orthopedic conglomerate, in November, 2013. Concurrent with Lanx, in July, 2006 Dr. Thramann was the founder and chairman of ProNerve, LLC ("ProNerve"). ProNerve was a healthcare services company that provided monitoring of nerve function during high risk surgical procedures affecting the brain and spinal cord. ProNerve was sold to Waud Capital Partners, a private equity firm, in 2012. Prior to ProNerve and concurrent with Lanx, Dr. Thramann was the founder and chairman of U.S. Radiosurgery (R). R is a healthcare services company that provides advanced radiosurgical treatments for tumors throughout the body. R became the largest provider of robotic guided CyberKnife treatments of such tumors in the U.S. and was sold to Alliance Healthcare Services (NASDAQ: AIQ) in April, 2011. From July, 2001 through April, 2008, Dr. Thramann was the founder and senior partner of Boulder Neurosurgical Associates, a neurosurgical practice serving Boulder County, Colorado. Dr. Thramann is the named inventor on over 100 U.S. and international issued and pending patents. He completed his neurosurgical residency and complex spinal reconstruction fellowship at the Barrow Neurological Institute in Phoenix, AZ, in June, 2001. He is a graduate of Cornell University Medical College in New York City and earned his Bachelor of Science degree in electrical engineering management at the U. S. Military Academy in st Point, NY.- Jeff Thramann自2020年9月起担任董事。彼亦自2021年3月起担任本公司执行董事。自本招股说明书发布之日起，他将过渡为执行主席。他负责监督公司的战略举措、资本化和治理。这包括日常参与与高级管理层合作，以建立公司的战略愿景，协助KOL发展，与首席执行官和首席财务官就财务计划、临床报销和产品战略进行合作，协助首席执行官招聘和聘用高级管理人员以及开展业务发展活动。他的职责还包括领导投资者关系工作、建立董事会和领导董事会会议。Thramann博士目前是Auddia Inc.的创始人兼执行主席。纳斯达克：AUUD，一家技术公司，正在通过人工智能平台重塑消费者与音频的互动方式，该平台可实现跨广播和播客收听的独特消费者体验。Thramann博士于2012年1月创立了Auddia Inc.。自2021年2月以来，他在Auddia担任过与在Aclarion类似的职务。2002年，Thramann博士是LANX，LLC（& # 8220；LANX & # 8221；）的创始人（并成为董事长）。Lanx是一家专注于脊柱植入物市场的创新医疗器械公司，通过推出其专利Aspen产品创造了棘间过程融合空间。Lanx于2013年11月被出售给国际骨科集团Biomet，Inc.。与Lanx同时，Thramann博士于2006年7月成为Pronerve，LLC（& # 8220；Pronerve & # 8221；）的创始人兼董事长。Pronerve是一家医疗保健服务公司，在影响大脑和脊髓的高风险外科手术中提供神经功能监测。Pronerve于2012年被出售给私募股权公司Waud Capital Partners。在加入Pronerve之前并与Lanx同时任职，Thramann博士是美国放射外科的创始人兼主席。USR是一家医疗保健服务公司，为全身肿瘤提供先进的放射外科治疗。USR成为美国最大的机器人引导射波刀治疗此类肿瘤的供应商，并于2011年4月出售给Alliance Healthcare Services（纳斯达克股票代码：医疗保健 0）。从2001年7月到2008年4月，Thramann博士是Boulder Neurosurgical Associates的创始人和高级合伙人，这是一家为科罗拉多州博尔德县提供服务的神经外科诊所。Thramann博士是100多项美国和国际已发布和正在申请的专利的指定发明人。他于2001年6月在亚利桑那州凤凰城的巴罗神经学研究所完成了他的神经外科住院医师和复杂脊柱重建奖学金。他毕业于纽约市康奈尔大学医学院，并在纽约西点军校获得电气工程管理理学学士学位。
- Jeff Thramann has been a director since September, 2020. He was also an executive Director since March of 2021, which is an executive officer of the Company. He transitioned to Executive Chairman at the time of April 2022 IPO. He oversees strategic initiatives, capitalization and governance at the company. This includes day to day involvement in working with senior management to establish the strategic vision of the Company, assist in KOL development, work with the Chief Executive Officer and Chief Financial Officer on financial plans, clinical reimbursement and product strategies, and assisting the Chief Executive Officer in recruitment and hiring of senior executives and the pursuit of biness development activities. His responsibilities also include leading investor relations efforts, building the board of directors and leading board meetings. Dr. Thramann is currently the founder and Executive Chairman of Auddia Inc. (NASDAQ: AUUD), a technology company that is reinventing how consumers interact with audio through an AI platform that enables unique consumer experiences across radio and podcast listening. Dr. Thramann founded Auddia Inc. in January 2012. In 2002, Dr. Thramann was the founder (and became the chairman) of Lanx, LLC ("Lanx"). Lanx was an innovative medical device company foced on the spinal implant market that created the interspino process fion space with the introduction of its patented Aspen product. Lanx was sold to Biomet, Inc., an international orthopedic conglomerate, in November, 2013. Concurrent with Lanx, in July, 2006 Dr. Thramann was the founder and chairman of ProNerve, LLC ("ProNerve"). ProNerve was a healthcare services company that provided monitoring of nerve function during high risk surgical procedures affecting the brain and spinal cord. ProNerve was sold to Waud Capital Partners, a private equity firm, in 2012. Prior to ProNerve and concurrent with Lanx, Dr. Thramann was the founder and chairman of U.S. Radiosurgery (R). R is a healthcare services company that provides advanced radiosurgical treatments for tumors throughout the body. R became the largest provider of robotic guided CyberKnife treatments of such tumors in the U.S. and was sold to Alliance Healthcare Services (NASDAQ: AIQ) in April, 2011. From July, 2001 through April, 2008, Dr. Thramann was the founder and senior partner of Boulder Neurosurgical Associates, a neurosurgical practice serving Boulder County, Colorado. Dr. Thramann is the named inventor on over 100 U.S. and international issued and pending patents. He completed his neurosurgical residency and complex spinal reconstruction fellowship at the Barrow Neurological Institute in Phoenix, AZ, in June, 2001. He is a graduate of Cornell University Medical College in New York City and earned his Bachelor of Science degree in electrical engineering management at the U. S. Military Academy in st Point, NY.
- Brent Ness
Brent Ness于2021年9月15日成为我们的首席执行官。从2019年12月到2021年4月，他担任顾问，然后成为Cleerly，Inc.的总裁兼首席商务官。Cleerly是支持AI的非侵入性数字护理途径的开发商，旨在提高临床医生对患者冠状动脉猝死风险的理解。在Cleerly，Ness先生共同领导与佳能公司建立合作伙伴关系，佳能公司共同营销Cleerly解决方案作为其产品的一部分。从2016年3月到2019年12月，Ness先生担任Mighty Oak Medical（& # 8220；Mighty Oak & # 8221；）的首席运营官，该公司的主要产品从FDA批准前发展到其名为Firefly的平台的国际全面市场推出。Firefly是一种3D打印的患者专用解决方案，旨在为脊柱外科医生提供一种高精度的替代方案，以替代脊柱导航空间中的导航和机器人应用。Firefly涉及使用CT扫描作为核心数据，根据这些数据创建复杂的术前计划以及指南和骨骼模型。从2014年到2016年，Ness先生担任Heartflow，Inc.（& # 8220；Heartflow & # 8221；）的首席商务官。HeartFlow是一家医疗技术公司，创建并开发了一种无创心脏测试，使医生能够为疑似冠心病患者做出更明智的决定。Ness先生领导的业务从FDA批准前到早期采用者网站的全球扩张。他与HeartFlow的高级领导团队一起，在SaaS平台的早期推出中部署了强大的临床循证方法，以吸引关键意见领袖医生和第三方付款人社区。这导致发布了III类CPT代码和多个私人付款人承保决定。从从2008年到2013年，他担任Pronerve，LLC（& # 8220；Pronerve”）的总裁。Pronerve是术中神经监测服务的提供商，涉及在脊柱和脑部手术期间使用各种电生理监测程序，以实现预警并避免对神经系统结构的损伤。作为Pronerve的总裁，Ness先生主持了高度分散的术中神经监测行业的总结。从2004年到2008年，Ness先生担任Medtronic Navigation（美敦力公司的一个部门）的全球销售与市场营销副总裁。在他职业生涯的早期，他曾受雇于通用电气医疗保健公司担任公司客户总监，并在飞利浦北美公司担任销售运营副总裁，这些公司是诊断成像设备的供应商。Ness目前担任Mighty Oak Medical、K2 Capital和Cleerly的顾问。Ness先生拥有北达科他大学市场营销学士学位和科罗拉多大学工商管理硕士学位。
Brent Ness became Chief Executive Officer on September 15, 2021. From December 2019 through April 2021, he was a consultant and then became President and Chief Commercial Officer of Cleerly, Inc., ("Cleerly"). Cleerly is a developer of an AI enabled non invasive digital care pathway aimed at improving clinicians understanding of their patients' risk of sudden coronary death. At Cleerly, Mr. Ness co led efforts to create a partnership with Canon, Inc. who co markets Cleerly solutions as part of their offerings. From March 2016 to December 2019, Mr. Ness was the Chief Operating Officer of Mighty Oak Medical ("Mighty Oak") whose principal products progressed from pre FDA clearance through an international full market launch of their platform called FIREFLY. FIREFLY is a 3D Printed patient specific solution that is intended to provide spine surgeons with a highly accurate alternative to navigation and robotic applications in the spinal navigation space. FIREFLY involves the e of CT scans as the core data upon which sophisticated pre surgical plans are created along with guides and bone models. From 2014 through 2016, Mr. Ness was the Chief Commercial Officer of HeartFlow, Inc., ("Heartflow"). HeartFlow is a medical technology company that created and developed a non invasive cardiac test enabling physicians to make more informed decisions for their patients with spected coronary heart disease. Mr. Ness led the biness from pre FDA clearance through a global expansion of early adopter sites. Along with the senior leadership team at HeartFlow, he deployed a strong clinical evidence based approach in the early launch of the SaaS platform to engage Key Opinion Leader Physicians and the third party payer community. This resulted in the issuance of Category III CPT Codes and multiple private payer coverage decisions. From 2008 through 2013, he was President of ProNerve, LLC, ("ProNerve"). ProNerve is a provider of intraoperative neuromonitoring services which involves the e of a variety of electro physiological monitoring procedures during spine and brain surgery, to allow early warning and avoidance of injury to nervo system structures. As President of ProNerve, Mr. Ness presided over a roll up of the highly fragmented Interoperative Nerve Monitoring Indtry. From 2004 to 2008, Mr. Ness served as Vice President Global Sales and Marketing for Medtronic Navigation, a division of Medtronic, Inc. Earlier in his career he was employed by GE Healthcare as Director of Corporate Accounts and for Philips North America as Vice President of Sales Operations, which companies are suppliers of diagnostic imaging equipment.- Brent Ness于2021年9月15日成为我们的首席执行官。从2019年12月到2021年4月，他担任顾问，然后成为Cleerly，Inc.的总裁兼首席商务官。Cleerly是支持AI的非侵入性数字护理途径的开发商，旨在提高临床医生对患者冠状动脉猝死风险的理解。在Cleerly，Ness先生共同领导与佳能公司建立合作伙伴关系，佳能公司共同营销Cleerly解决方案作为其产品的一部分。从2016年3月到2019年12月，Ness先生担任Mighty Oak Medical（& # 8220；Mighty Oak & # 8221；）的首席运营官，该公司的主要产品从FDA批准前发展到其名为Firefly的平台的国际全面市场推出。Firefly是一种3D打印的患者专用解决方案，旨在为脊柱外科医生提供一种高精度的替代方案，以替代脊柱导航空间中的导航和机器人应用。Firefly涉及使用CT扫描作为核心数据，根据这些数据创建复杂的术前计划以及指南和骨骼模型。从2014年到2016年，Ness先生担任Heartflow，Inc.（& # 8220；Heartflow & # 8221；）的首席商务官。HeartFlow是一家医疗技术公司，创建并开发了一种无创心脏测试，使医生能够为疑似冠心病患者做出更明智的决定。Ness先生领导的业务从FDA批准前到早期采用者网站的全球扩张。他与HeartFlow的高级领导团队一起，在SaaS平台的早期推出中部署了强大的临床循证方法，以吸引关键意见领袖医生和第三方付款人社区。这导致发布了III类CPT代码和多个私人付款人承保决定。从从2008年到2013年，他担任Pronerve，LLC（& # 8220；Pronerve”）的总裁。Pronerve是术中神经监测服务的提供商，涉及在脊柱和脑部手术期间使用各种电生理监测程序，以实现预警并避免对神经系统结构的损伤。作为Pronerve的总裁，Ness先生主持了高度分散的术中神经监测行业的总结。从2004年到2008年，Ness先生担任Medtronic Navigation（美敦力公司的一个部门）的全球销售与市场营销副总裁。在他职业生涯的早期，他曾受雇于通用电气医疗保健公司担任公司客户总监，并在飞利浦北美公司担任销售运营副总裁，这些公司是诊断成像设备的供应商。Ness目前担任Mighty Oak Medical、K2 Capital和Cleerly的顾问。Ness先生拥有北达科他大学市场营销学士学位和科罗拉多大学工商管理硕士学位。
- Brent Ness became Chief Executive Officer on September 15, 2021. From December 2019 through April 2021, he was a consultant and then became President and Chief Commercial Officer of Cleerly, Inc., ("Cleerly"). Cleerly is a developer of an AI enabled non invasive digital care pathway aimed at improving clinicians understanding of their patients' risk of sudden coronary death. At Cleerly, Mr. Ness co led efforts to create a partnership with Canon, Inc. who co markets Cleerly solutions as part of their offerings. From March 2016 to December 2019, Mr. Ness was the Chief Operating Officer of Mighty Oak Medical ("Mighty Oak") whose principal products progressed from pre FDA clearance through an international full market launch of their platform called FIREFLY. FIREFLY is a 3D Printed patient specific solution that is intended to provide spine surgeons with a highly accurate alternative to navigation and robotic applications in the spinal navigation space. FIREFLY involves the e of CT scans as the core data upon which sophisticated pre surgical plans are created along with guides and bone models. From 2014 through 2016, Mr. Ness was the Chief Commercial Officer of HeartFlow, Inc., ("Heartflow"). HeartFlow is a medical technology company that created and developed a non invasive cardiac test enabling physicians to make more informed decisions for their patients with spected coronary heart disease. Mr. Ness led the biness from pre FDA clearance through a global expansion of early adopter sites. Along with the senior leadership team at HeartFlow, he deployed a strong clinical evidence based approach in the early launch of the SaaS platform to engage Key Opinion Leader Physicians and the third party payer community. This resulted in the issuance of Category III CPT Codes and multiple private payer coverage decisions. From 2008 through 2013, he was President of ProNerve, LLC, ("ProNerve"). ProNerve is a provider of intraoperative neuromonitoring services which involves the e of a variety of electro physiological monitoring procedures during spine and brain surgery, to allow early warning and avoidance of injury to nervo system structures. As President of ProNerve, Mr. Ness presided over a roll up of the highly fragmented Interoperative Nerve Monitoring Indtry. From 2004 to 2008, Mr. Ness served as Vice President Global Sales and Marketing for Medtronic Navigation, a division of Medtronic, Inc. Earlier in his career he was employed by GE Healthcare as Director of Corporate Accounts and for Philips North America as Vice President of Sales Operations, which companies are suppliers of diagnostic imaging equipment.
- Ryan Bond
Ryan Bond，从2021年9月开始，Bond先生一直担任我们的首席战略官。从2018年12月到2021年8月，他一直担任我们的业务发展副总裁，负责业务发展，包括Aclarion基于云的SaaS的有限商业发布，与美国、欧盟和英国的早期采用者合作，Bond先生协调了由我们的客户赞助的多项研究试验，其中采用了Aclarion的专有辅助诊断技术。Bond先生在与报销顾问合作以获得具有指定APC费率的Aclarion的III类CPT代码方面发挥了重要作用，并倡导CMS取消长期未覆盖的磁共振光谱MRS政策，CPT代码76390。2014年11月至2018年9月，邦德先生担任全球脊柱市场公司NuVasive的医疗保健解决方案总监。在NuVasive期间，他领导了多项战略计划，涉及战略合作伙伴关系、渠道开发、定价、合同和销售培训。从2005年到2014年，邦德先生在Accelero Health Partners（& # 8220；Accelero & # 8221；）工作，这是一家专注于肌肉骨骼服务线开发的咨询公司，结合了战略组织发展计划和专有的基于云的商业智能工具，离散测量了一系列临床、功能、运营和基于数量的指标，同时说明每一种相互关联的因果关系。2006年，Accelero被Zimmer Holdings收购。邦德先生在俄亥俄大学商学院的顾问委员会任职，在那里他获得了拉斯工程与技术学院的工程学学士学位。
Ryan Bond became Chief Strategy Officer in September 2021, leading worldwide strategic initiatives and ctomer engagements. From December 2018 to Augt 2021, he has been Vice President, Biness Development, where he led biness development, sales and marketing including a limited commercial launch of Aclarion's cloud based SaaS with early adopters in the , EU, and UK. Mr. Bond coordinated multiple research trials sponsored by ctomers, where Aclarion's proprietary, adjunctive diagnostic technology is employed. Mr. Bond was instrumental in working with reimbursement consultants to gain Category III CPT Codes for Aclarion with assigned APC rates and advocating to CMS for the removal of a long standing non coverage policy for magnetic resonance spectroscopy (MRS, CPT Code 76390). From November 2014 to September 2018 Mr. Bond was Director, Healthcare Solutions at NuVasive, a company in the global spine market. While at NuVasive, he led several strategic initiatives involving strategic partnerships, channel development, pricing, contracting, and sales training. From 2005 to 2014, Mr. Bond was with Accelero Health Partners ("Accelero"), a consulting firm foced on mculoskeletal service line development ing a combination of strategic organizational development programs and a proprietary cloud based biness intelligence tool that discretely measured a cadre of clinical, functional, operational, and volume based metrics, while simultaneoly illtrating the interrelated cae effect of each. In 2006, Accelero was acquired by Zimmer Holdings. Mr. Bond serves on an Advisory Board with the Center for Entrepreneurship at Ohio University, where he earned a Bachelor's of Science Degree in Engineering from the Rs College of Engineering and Technology.- Ryan Bond，从2021年9月开始，Bond先生一直担任我们的首席战略官。从2018年12月到2021年8月，他一直担任我们的业务发展副总裁，负责业务发展，包括Aclarion基于云的SaaS的有限商业发布，与美国、欧盟和英国的早期采用者合作，Bond先生协调了由我们的客户赞助的多项研究试验，其中采用了Aclarion的专有辅助诊断技术。Bond先生在与报销顾问合作以获得具有指定APC费率的Aclarion的III类CPT代码方面发挥了重要作用，并倡导CMS取消长期未覆盖的磁共振光谱MRS政策，CPT代码76390。2014年11月至2018年9月，邦德先生担任全球脊柱市场公司NuVasive的医疗保健解决方案总监。在NuVasive期间，他领导了多项战略计划，涉及战略合作伙伴关系、渠道开发、定价、合同和销售培训。从2005年到2014年，邦德先生在Accelero Health Partners（& # 8220；Accelero & # 8221；）工作，这是一家专注于肌肉骨骼服务线开发的咨询公司，结合了战略组织发展计划和专有的基于云的商业智能工具，离散测量了一系列临床、功能、运营和基于数量的指标，同时说明每一种相互关联的因果关系。2006年，Accelero被Zimmer Holdings收购。邦德先生在俄亥俄大学商学院的顾问委员会任职，在那里他获得了拉斯工程与技术学院的工程学学士学位。
- Ryan Bond became Chief Strategy Officer in September 2021, leading worldwide strategic initiatives and ctomer engagements. From December 2018 to Augt 2021, he has been Vice President, Biness Development, where he led biness development, sales and marketing including a limited commercial launch of Aclarion's cloud based SaaS with early adopters in the , EU, and UK. Mr. Bond coordinated multiple research trials sponsored by ctomers, where Aclarion's proprietary, adjunctive diagnostic technology is employed. Mr. Bond was instrumental in working with reimbursement consultants to gain Category III CPT Codes for Aclarion with assigned APC rates and advocating to CMS for the removal of a long standing non coverage policy for magnetic resonance spectroscopy (MRS, CPT Code 76390). From November 2014 to September 2018 Mr. Bond was Director, Healthcare Solutions at NuVasive, a company in the global spine market. While at NuVasive, he led several strategic initiatives involving strategic partnerships, channel development, pricing, contracting, and sales training. From 2005 to 2014, Mr. Bond was with Accelero Health Partners ("Accelero"), a consulting firm foced on mculoskeletal service line development ing a combination of strategic organizational development programs and a proprietary cloud based biness intelligence tool that discretely measured a cadre of clinical, functional, operational, and volume based metrics, while simultaneoly illtrating the interrelated cae effect of each. In 2006, Accelero was acquired by Zimmer Holdings. Mr. Bond serves on an Advisory Board with the Center for Entrepreneurship at Ohio University, where he earned a Bachelor's of Science Degree in Engineering from the Rs College of Engineering and Technology.
- Gregory Gould
Gregory Gould，2014年6月起，他就职于公司。2012年4月至2014年6月，他在Gould, LLC担任生物技术业的财务与运营顾问。担任顾问之前，2006年11月至2012年4月，他担任SeraCare Life Sciences, Inc.的首席财务官、秘书和会计长，该公司是诊断、治疗与药物开发市场生物产品制造商和服务供应商。2011年7月至2012年4月，他担任SeraCare Life Sciences, Inc.的临时总裁和首席执行官；2004至2005年，他担任Atrix Laboratories, Inc.的首席财务官、会计长和秘书， 该公司是专注先进药物输送的制药公司。他在Arthur Andersen, LLP开始职业生涯。他目前是上市药物开发公司CytoDyn, Inc.的董事会成员以及Luoxis Diagnostics, Inc.和Vyrix Pharmaceuticals, Inc.的首席财务官、会计长和秘书。他在Colorado大学获得工商管理学士学位，是一名注册会计师。
Gregory Gould became Chief Financial Officer in September 2025. He is a seasoned public company finance executive with more than 20 years of experience serving as Chief Financial Officer for publicly traded and privately held companies in the biopharmaceutical, medical device and national llness sectors. He is a Certified Public Accountant with significant experience building and leading accounting organizations, strengthening internal controls, and developing scalable financial reporting infrastructures to support growth. From January 2023 until September 2025, Mr. Gould served as Chief Financial Officer of Nanos Health LLC, a pre revenue pharmaceutical company focused on advancing drug delivery solutions through nanotechnology. From June 2022 to December 2022, he served as Chief Financial Officer of Charlotte's b Holdings, Inc. (TSX: CB; OTCQB: CWBHF), a publicly traded leader in hemp extract and botanical based llness products. From July 2021 to June 2022, he served as Chief Financial Officer of AJNA Biosciences PBC, a privately held botanical drug development company. From October 2018 to July 2021, Mr. Gould served as Chief Financial Officer and Chief Administrative Officer of NewAge, Inc. (NASDAQ: NBEV), where he oversaw SEC reporting, financial planning and analysis, treasury, internal controls, and administrative functions. Following his departure, NewAge filed a voluntary petition for relief under Chapter 11 of the U.S. Bankruptcy Code on August 30, 2022. Earlier in his career, Mr. Gould served as Chief Financial Officer of several publicly traded healthcare and life sciences companies, including SeraCare Life Sciences, Atrix Laboratories, and Colorado MedTech. In these roles, he led SEC reporting and public company compliance, capital raising activities, and strategic transactions, including the successful sale of SeraCare Life Sciences, Atrix Laboratories, and Colorado MedTech to strategic acquirors, delivering value to shareholders. He also previoly served as Chief Financial Officer of Aytu BioPharma, Ampio Pharmaceuticals and Evolve Biologics (a division of Therapure Biopharma). Mr. Gould serves as a member of the Board of Trtees of Cook Media Global, a multinational Christian publishing and mic company. He began his career as an auditor with Arthur Andersen LLP. Mr. Gould holds a Bachelor of Science degree in Biness Administration from the University of Colorado at Boulder.- Gregory Gould，2014年6月起，他就职于公司。2012年4月至2014年6月，他在Gould, LLC担任生物技术业的财务与运营顾问。担任顾问之前，2006年11月至2012年4月，他担任SeraCare Life Sciences, Inc.的首席财务官、秘书和会计长，该公司是诊断、治疗与药物开发市场生物产品制造商和服务供应商。2011年7月至2012年4月，他担任SeraCare Life Sciences, Inc.的临时总裁和首席执行官；2004至2005年，他担任Atrix Laboratories, Inc.的首席财务官、会计长和秘书， 该公司是专注先进药物输送的制药公司。他在Arthur Andersen, LLP开始职业生涯。他目前是上市药物开发公司CytoDyn, Inc.的董事会成员以及Luoxis Diagnostics, Inc.和Vyrix Pharmaceuticals, Inc.的首席财务官、会计长和秘书。他在Colorado大学获得工商管理学士学位，是一名注册会计师。
- Gregory Gould became Chief Financial Officer in September 2025. He is a seasoned public company finance executive with more than 20 years of experience serving as Chief Financial Officer for publicly traded and privately held companies in the biopharmaceutical, medical device and national llness sectors. He is a Certified Public Accountant with significant experience building and leading accounting organizations, strengthening internal controls, and developing scalable financial reporting infrastructures to support growth. From January 2023 until September 2025, Mr. Gould served as Chief Financial Officer of Nanos Health LLC, a pre revenue pharmaceutical company focused on advancing drug delivery solutions through nanotechnology. From June 2022 to December 2022, he served as Chief Financial Officer of Charlotte's b Holdings, Inc. (TSX: CB; OTCQB: CWBHF), a publicly traded leader in hemp extract and botanical based llness products. From July 2021 to June 2022, he served as Chief Financial Officer of AJNA Biosciences PBC, a privately held botanical drug development company. From October 2018 to July 2021, Mr. Gould served as Chief Financial Officer and Chief Administrative Officer of NewAge, Inc. (NASDAQ: NBEV), where he oversaw SEC reporting, financial planning and analysis, treasury, internal controls, and administrative functions. Following his departure, NewAge filed a voluntary petition for relief under Chapter 11 of the U.S. Bankruptcy Code on August 30, 2022. Earlier in his career, Mr. Gould served as Chief Financial Officer of several publicly traded healthcare and life sciences companies, including SeraCare Life Sciences, Atrix Laboratories, and Colorado MedTech. In these roles, he led SEC reporting and public company compliance, capital raising activities, and strategic transactions, including the successful sale of SeraCare Life Sciences, Atrix Laboratories, and Colorado MedTech to strategic acquirors, delivering value to shareholders. He also previoly served as Chief Financial Officer of Aytu BioPharma, Ampio Pharmaceuticals and Evolve Biologics (a division of Therapure Biopharma). Mr. Gould serves as a member of the Board of Trtees of Cook Media Global, a multinational Christian publishing and mic company. He began his career as an auditor with Arthur Andersen LLP. Mr. Gould holds a Bachelor of Science degree in Biness Administration from the University of Colorado at Boulder.